Abstract
Leishmaniasis, a complex disease caused by at least 20 species of unicellular parasites of the genus Leishmania, disproportionately affects impoverished regions of about 90 tropical and sub-tropical countries. Currently available antileishmanial therapies, particularly for visceral leishmaniasis, are severely limited, with treatment outcome depending on many factors, including the immune status of the patient, comorbidities, malnutrition, and socio-economic conditions in the patient’s geographic location. There is an urgent need for new therapeutics, particularly new effective oral drugs, for visceral leishmaniasis. Despite the availability of the Leishmania genome sequence information and significant research into the biology of the parasites, antileishmanial drug development is hampered by the lack of knowledge about druggable targets in the parasite and difficulties in identifying the molecular targets of compounds that show activity. In this context, we analyzed recent progress in antileishmanial drug development programs, which take advantage of different powerful approaches, such as high-throughput screening of compound libraries, recent developments in genetic methods for assessing essentiality of parasite genes, and chemical, genetic, and proteomics-based target discovery and target validation methods.
Keywords: Leishmaniasis, phenotypic screening, target-based screening, CRISP/Cas9, cosmid library, proteasome, N-myristoylation, cyclin-dependent kinase.
Current Medicinal Chemistry
Title:Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies
Volume: 28 Issue: 31
Author(s): Pavan K. Mantravadi, Anutthaman Parthasarathy and Karunakaran Kalesh*
Affiliation:
- Department of Chemistry, Durham University, Lower Mount Joy, South Road, Durham DH1 3LE,United Kingdom
Keywords: Leishmaniasis, phenotypic screening, target-based screening, CRISP/Cas9, cosmid library, proteasome, N-myristoylation, cyclin-dependent kinase.
Abstract: Leishmaniasis, a complex disease caused by at least 20 species of unicellular parasites of the genus Leishmania, disproportionately affects impoverished regions of about 90 tropical and sub-tropical countries. Currently available antileishmanial therapies, particularly for visceral leishmaniasis, are severely limited, with treatment outcome depending on many factors, including the immune status of the patient, comorbidities, malnutrition, and socio-economic conditions in the patient’s geographic location. There is an urgent need for new therapeutics, particularly new effective oral drugs, for visceral leishmaniasis. Despite the availability of the Leishmania genome sequence information and significant research into the biology of the parasites, antileishmanial drug development is hampered by the lack of knowledge about druggable targets in the parasite and difficulties in identifying the molecular targets of compounds that show activity. In this context, we analyzed recent progress in antileishmanial drug development programs, which take advantage of different powerful approaches, such as high-throughput screening of compound libraries, recent developments in genetic methods for assessing essentiality of parasite genes, and chemical, genetic, and proteomics-based target discovery and target validation methods.
Export Options
About this article
Cite this article as:
Mantravadi K. Pavan, Parthasarathy Anutthaman and Kalesh Karunakaran *, Antileishmanial Drug Development: A Review of Modern Molecular Chemical Tools and Research Strategies, Current Medicinal Chemistry 2021; 28 (31) . https://dx.doi.org/10.2174/0929867328666201125121018
DOI https://dx.doi.org/10.2174/0929867328666201125121018 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Synthesis, Structural Modification and Mode of Anticancer Action of Evodiamine: A Review
Recent Patents on Anti-Cancer Drug Discovery Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples
Current Pharmaceutical Analysis Pharmacological Cyclin-Dependent Kinase Inhibitors (PCIs) as Potential Antiviral Drugs
Anti-Infective Agents in Medicinal Chemistry Cyclodextrin Complexation of Meclizine Hydrochloride and its Influence on the Solubility for its Repurposing
Drug Delivery Letters High Throughput Screening of Physicochemical Properties and In Vitro ADME Profiling in Drug Discovery
Combinatorial Chemistry & High Throughput Screening Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis
Current Medical Imaging Current Advances in Antibody Immobilization on Different Surfaces and Beads
Current Proteomics Bioactivity of Hybrid Polymeric Magnetic Nanoparticles and Their Applications in Drug Delivery
Current Pharmaceutical Design Determination of Three Tyrosine Kinase Inhibitors and One Active Metabolite by an Identical and Validated Ultra-performance Liquid Chromatography-DAD Method in Human Plasma
Current Pharmaceutical Analysis Development and Certification of Formononetin Reference Material for Quality Control of Functional Foods and Botanical Supplements
Current Analytical Chemistry Aptamers and New Bioreceptors for the Electrochemical Detection of Biomarkers Expressed in Hepatocellular Carcinoma
Current Medicinal Chemistry Cystine Dimethyl Ester Induces Apoptosis Through Regulation of PKC-δ and PKC-ε in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry AP5346 (ProLindac™), A DACH Platinum Polymer Conjugate in Phase II Trials Against Ovarian Cancer
Current Bioactive Compounds Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Identification of Multiple Subcellular Locations for Proteins in Budding Yeast
Current Bioinformatics Novel Hydroxamate and Anilide Derivatives as Potent Histone Deacetylase Inhibitors: Synthesis and Antiproliferative Evaluation
Current Medicinal Chemistry A First QSAR Model for Galectin-3 Glycomimetic Inhibitors Based on 3D Docked Structures
Medicinal Chemistry Synthesis and Biological Evaluation of Licofelone Derivatives as Anticancer and Anti-inflammatory Agents
Letters in Drug Design & Discovery Small Molecules Modulating AHL-based Quorum Sensing to Attenuate Bacteria Virulence and Biofilms as Promising Antimicrobial Drugs
Current Medicinal Chemistry